Merck gets FDA nod for Ebola vaccine

Dec. 20, 2019

The U.S. FDA approved Merck & Co’s Ebola vaccine Ervebo, making it the first FDA-approved vaccine against the deadly virus.

The vaccine was used by the World Health Organization and Democratic Republic of the Congo as an investigational vaccine to help reduce Ebola outbreaks in West African countries from 2014 to 2016. In November, Merck received approval from the European Commission to market Ervebo in the EU. 

The ongoing outbreak has killed more than 2,100 people in Congo since the middle of the year, making it the second-largest Ebola outbreak in history.

Ervebo, which is administered as a single-dose injection, will help to prevent EVD caused by Zaire ebolavirus in patients aged 18 years and older.

Read the press release